Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 3
1991 2
1993 1
1994 1
1995 5
1996 3
1997 5
1998 3
1999 5
2000 2
2001 3
2004 2
2005 4
2006 8
2007 7
2008 6
2009 6
2010 2
2011 5
2012 3
2013 6
2014 6
2015 7
2016 6
2017 5
2018 6
2019 1
2020 2
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Baumeister SH, et al. Among authors: sentman cl. Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5. Cancer Immunol Res. 2019. PMID: 30396908 Free PMC article. Clinical Trial.
Bispecific T-cell engagers for cancer immunotherapy.
Huehls AM, Coupet TA, Sentman CL. Huehls AM, et al. Among authors: sentman cl. Immunol Cell Biol. 2015 Mar;93(3):290-6. doi: 10.1038/icb.2014.93. Epub 2014 Nov 4. Immunol Cell Biol. 2015. PMID: 25367186 Free PMC article. Review.
NKG2D ligands as therapeutic targets.
Spear P, Wu MR, Sentman ML, Sentman CL. Spear P, et al. Among authors: sentman cl. Cancer Immun. 2013 May 1;13:8. Print 2013. Cancer Immun. 2013. PMID: 23833565 Free PMC article. Review.
Regulatory T cell-based therapies for autoimmunity.
Arellano B, Graber DJ, Sentman CL. Arellano B, et al. Among authors: sentman cl. Discov Med. 2016 Aug;22(119):73-80. Discov Med. 2016. PMID: 27585233 Free PMC article. Review.
NKG2D CARs as cell therapy for cancer.
Sentman CL, Meehan KR. Sentman CL, et al. Cancer J. 2014 Mar-Apr;20(2):156-9. doi: 10.1097/PPO.0000000000000029. Cancer J. 2014. PMID: 24667963 Free PMC article. Review.
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.
Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S. Rajasekaran K, et al. Among authors: sentman cl. Front Immunol. 2016 May 12;7:176. doi: 10.3389/fimmu.2016.00176. eCollection 2016. Front Immunol. 2016. PMID: 27242783 Free PMC article. Review.
Exploiting natural killer group 2D receptors for CAR T-cell therapy.
Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Demoulin B, et al. Among authors: sentman cl. Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14. Future Oncol. 2017. PMID: 28613086 Free article. Review.
113 results